EYPT - EyePoint Pharmaceuticals Inc Stock Price, Fair Value and News

11.83USD-0.69 (-5.51%)Delayed

Market Summary

USD11.83-0.69

Delayed

-5.51%

EYPT Alerts

1 major insider buys recently.

Big jump in Revenue (Y/Y)
Big fall in earnings (Y/Y)
Losses in recent quarter

EYPT Stock Price

View Fullscreen

EYPT RSI Chart

EYPT Valuation

Market Cap

616.2M

Price/Earnings (Trailing)

-7.81

Price/Sales (Trailing)

12.32

EV/EBITDA

-4.94

Price/Free Cashflow

-37

EYPT Price/Sales (Trailing)

EYPT Profitability

EBT Margin

-141.37%

Return on Equity

-31.57%

Return on Assets

-23.97%

Free Cashflow Yield

-2.7%

EYPT Fundamentals

EYPT Revenue

Revenue (TTM)

50.0M

Rev. Growth (Yr)

52.08%

Rev. Growth (Qtr)

-16.71%

EYPT Earnings

Earnings (TTM)

-78.9M

Earnings Growth (Yr)

-38.37%

Earnings Growth (Qtr)

-107.7%

Breaking Down EYPT Revenue

Last 7 days

-2.1%

Last 30 days

-43.5%

Last 90 days

-58.2%

Trailing 12 Months

93.0%

How does EYPT drawdown profile look like?

EYPT Financial Health

Current Ratio

5.08

EYPT Investor Care

Shares Dilution (1Y)

51.84%

Diluted EPS (TTM)

-1.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	50.0M	0	0	0
2023	39.8M	37.3M	42.5M	46.0M
2022	38.9M	41.5M	42.4M	41.4M
2021	34.3M	39.2M	32.5M	36.9M
2020	25.8M	22.8M	35.9M	34.4M
2019	5.7M	12.2M	14.2M	20.4M
2018	2.9M	3.0M	3.1M	4.6M
2017	6.1M	7.5M	7.6M	2.6M
2016	7.9M	1.6M	3.1M	4.6M
2015	26.4M	26.6M	20.3M	14.1M
2014	3.7M	3.5M	28.2M	28.1M
2013	2.4M	2.1M	2.2M	2.2M
2012	6.5M	3.5M	2.4M	2.4M
2011	9.5M	5.0M	6.1M	6.4M
2010	0	23.1M	18.5M	14.0M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of EyePoint Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 06, 2024	cormorant asset management, lp	bought	10,081,700	11.8608	850,000	-
Apr 18, 2024	cormorant asset management, lp	bought	10,489,400	18.0304	581,765	-
Mar 30, 2024	paggiarino dario a.	sold (taxes)	-528,036	20.67	-25,546	chief medical officer
Mar 30, 2024	paggiarino dario a.	acquired	-	-	50,404	chief medical officer
Feb 27, 2024	duker jay s.	gifted	-	-	-2,500	president and ceo
Feb 27, 2024	duker jay s.	gifted	-	-	2,500	president and ceo
Feb 20, 2024	duker jay s.	gifted	-	-	20,000	president and ceo
Feb 20, 2024	duker jay s.	gifted	-	-	-20,000	president and ceo
Feb 13, 2024	lurker nancy	gifted	-	-	74,681	executive vice chair
Feb 13, 2024	lurker nancy	gifted	-	-	-74,681	executive vice chair

Which funds bought or sold EYPT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Ikarian Capital, LLC	reduced	-99.72	-8,485,840	21,642	-%
May 16, 2024	COMERICA BANK	added	150	13,410	24,202	-%
May 16, 2024	JANE STREET GROUP, LLC	added	207	2,822,450	4,437,720	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	884	792,879	894,494	-%
May 15, 2024	VR Adviser, LLC	unchanged	-	-610,000	5,167,500	0.25%
May 15, 2024	Cinctive Capital Management LP	sold off	-100	-462,200	-	-%
May 15, 2024	Ghost Tree Capital, LLC	reduced	-45.45	-1,952,850	1,860,300	0.52%
May 15, 2024	Gotham Asset Management, LLC	added	143	358,411	662,515	0.01%
May 15, 2024	Cormorant Asset Management, LP	added	14.16	2,939,560	142,483,000	6.25%
May 15, 2024	Essex Woodlands Management, Inc.	reduced	-33.63	-21,956,300	32,069,900	9.30%

Are Funds Buying or Selling EYPT?

Are funds buying EYPT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EYPT

No. of Funds

Unveiling EyePoint Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 01, 2024	adage capital management, l.p.	9.90%	5,156,299	SC 13G/A
Apr 30, 2024	adage capital management, l.p.	10.35%	5,156,299	SC 13G
Feb 14, 2024	price t rowe associates inc /md/	5.6%	2,522,704	SC 13G
Feb 14, 2024	ra capital management, l.p.	6.1%	3,095,136	SC 13G/A
Feb 13, 2024	suvretta capital management, llc	9.99%	4,774,389	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	9.15%	4,466,420	SC 13G/A
Feb 06, 2024	franklin resources inc	9.5%	4,640,651	SC 13G/A
Dec 14, 2023	cormorant asset management, lp	12.36%	6,038,235	SC 13G/A
Dec 08, 2023	ew healthcare partners, l.p.	4.8%	2,247,432	SC 13D/A
Sep 11, 2023	franklin resources inc	11.8%	4,130,137	SC 13G/A

Recent SEC filings of EyePoint Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	4	Insider Trading
May 14, 2024	144	Notice of Insider Sale Intent
May 09, 2024	10-Q	Quarterly Report
May 08, 2024	4	Insider Trading
May 08, 2024	8-K	Current Report
May 06, 2024	8-K	Current Report
May 01, 2024	SC 13G/A	Major Ownership Report
Apr 30, 2024	SC 13G	Major Ownership Report
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A

Peers (Alternatives to EyePoint Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

EyePoint Pharmaceuticals Inc News

Latest updates

EyePoint Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-16.7%	11,684,000	14,028,000	15,202,000	9,105,000	7,683,000	10,533,000	10,012,000	11,565,000	9,294,000	11,544,000	9,059,000	9,013,000	7,323,000	7,131,000	15,695,000	4,122,000	7,489,000	8,634,000	2,509,000	7,210,000	2,012,000
Operating Expenses	-100.0%	-	30,382,000	29,600,000	31,866,000	29,237,000	54,270,000	28,410,000	30,781,000	27,578,000	29,593,500	24,372,000	19,992,000	18,258,000	19,868,000	17,652,000	15,274,000	18,933,000	17,618,500	16,569,000	17,375,000	16,663,000
S&GA Expenses	-96.8%	6,000	185,000	479,000	5,288,000	5,737,000	5,915,000	6,016,000	6,883,000	6,693,000	7,811,000	7,374,000	6,659,000	5,659,000	5,810,000	5,269,000	6,089,000	8,125,000	7,399,000	7,778,000	7,284,000	7,311,000
R&D Expenses	67.9%	30,139,000	17,951,000	17,363,000	15,730,000	13,618,000	15,543,000	11,162,000	12,992,000	9,945,000	8,918,000	8,498,000	5,605,000	5,479,000	5,205,000	4,090,000	3,276,000	4,853,000	4,131,500	3,484,000	3,955,000	3,797,000
EBITDA Margin	6.9%	-1.40	-1.50	-2.35	-2.65	-2.49	-2.38	-1.16	-1.17	-1.22	-1.28	-1.44	-1.19	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	435,000	812,000	781,000	662,000	552,000	1,194,000	1,388,000	1,388,000	1,376,000	1,346,000	1,827,000	1,840,000	1,806,000	1,784,000	1,787,000	1,770,000	1,599,000	1,020,000
EBT Margin	8.0%	-1.41	-1.54	-2.40	-2.74	-2.57	-2.47	-1.25	-1.28	-1.37	-1.44	-1.63	-1.36	-	-	-	-	-	-	-	-	-
Net Income	-107.7%	-29,284,000	-14,099,000	-12,612,000	-22,920,000	-21,164,000	-43,452,000	-18,420,000	-19,406,000	-20,976,000	-19,432,000	-16,695,000	-10,010,000	-12,280,000	-15,469,000	-3,801,000	-12,950,000	-13,174,000	-10,410,000	-15,647,000	-11,498,000	-19,238,000
Net Income Margin	-2.6%	-1.58	-1.54	-2.36	-2.84	-2.57	-2.47	-1.84	-1.85	-1.72	-1.58	-1.67	-1.06	-	-	-	-	-	-	-	-	-
Free Cashflow	-34.9%	-32,365,000	-23,992,000	-16,924,000	56,627,000	-17,319,000	-13,173,000	-14,334,000	-19,341,000	-20,307,000	-16,668,000	-7,918,000	-10,568,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-7.3%	329	355	160	176	155	180	220	233	245	263	168	179	187	92.00	77.00	70.00	80.00	73.00	79.00	91.00	82.00
Current Assets	-7.9%	318	345	150	167	146	173	192	206	220	238	142	152	159	63.00	48.00	40.00	50.00	42.00	47.00	59.00	48.00
Cash Equivalents	-3.6%	271	281	133	140	106	96.00	75.00	82.00	102	179	120	128	139	45.00	29.00	23.00	26.00	22.00	32.00	44.00	44.00
Inventory	9.0%	4.00	4.00	5.00	4.00	4.00	3.00	4.00	3.00	3.00	4.00	5.00	5.00	6.00	5.00	4.00	4.00	3.00	2.00	3.00	2.00	1.00
Net PPE	27.2%	7.00	5.00	4.00	3.00	3.00	1.00	1.00	1.00	1.00	0.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-10.7%	79.00	89.00	101	118	76.00	84.00	84.00	82.00	78.00	79.00	76.00	72.00	71.00	73.00	69.00	65.00	64.00	65.00	63.00	63.00	62.00
Current Liabilities	-1.1%	63.00	63.00	64.00	69.00	27.00	35.00	34.00	33.00	32.00	24.00	20.00	16.00	13.00	15.00	13.00	10.00	10.00	12.00	10.00	11.00	25.00
Short Term Borrowings	-	-	-	-	-	5.00	10.00	10.00	10.00	10.00	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	-	-	-	-	-	29.00	29.00	29.00	29.00	29.00	37.00	36.00	36.00	38.00	38.00	51.00	50.00	48.00	47.00	47.00	46.00	32.00
LT Debt, Non Current	-	-	-	-	-	29.00	29.00	29.00	29.00	29.00	37.00	36.00	36.00	38.00	38.00	51.00	50.00	48.00	47.00	47.00	46.00	32.00
Shareholder's Equity	-6.2%	250	266	59.00	57.00	78.00	96.00	136	151	167	184	93.00	107	116	19.00	8.00	4.00	16.00	8.00	16.00	28.00	20.00
Retained Earnings	-3.9%	-771	-742	-728	-715	-692	-671	-627	-609	-590	-569	-549	-532	-522	-510	-495	-491	-478	-465	-454	-439	-427
Additional Paid-In Capital	1.3%	1,020	1,008	786	772	770	767	764	760	756	753	642	639	638	528	502	495	494	473	470	466	447
Shares Outstanding	1.7%	50.00	49.00	35.00	34.00	34.00	34.00	37.00	37.00	37.00	34.00	27.00	29.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	233	-	-	-	210	-	-	-	192	-	-	-	62.00	-	-	-	101	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-34.9%	-31,171	-23,109	-15,204	57,023	-16,835	-12,588	-13,136	-19,123	-20,158	-16,668	-7,787	-10,543	-15,099	5,895	1,136	-5,121	-16,345	-11,486	-14,772	-17,107	-13,334
Share Based Compensation	253.7%	12,699	3,590	3,629	1,788	3,050	3,361	3,199	4,140	3,477	2,808	2,471	1,180	988	1,263	2,389	735	1,160	857	977	1,496	1,238
Cashflow From Investing	144.1%	20,806	-47,148	-1,720	13,467	32,086	32,917	6,272	-12.00	-56,442	-32,965	-131	-25.00	-	-192	-128	-26.00	-16.00	-6.00	-	-25.00	-182
Cashflow From Financing	-99.9%	115	218,485	10,362	-36,658	-5,119	-58.00	92.00	-276	-448	108,516	-2.00	-381	108,769	10,480	4,904	1,662	20,446	1,945	2,371	17,914	11,634

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

EYPT Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 11,684	$ 7,683
Operating expenses:
Cost of sales	759	640
Research and development	30,139	13,618
Sales and marketing	6	5,737
General and administrative	14,101	9,242
Total operating expenses	45,005	29,237
Loss from operations	(33,321)	(21,554)
Other (expense) income:
Interest and other income, net	4,037	1,202
Interest expense	0	(812)
Total other (expense) income, net	4,037	390
Net loss	$ (29,284)	$ (21,164)
Net loss per share - basic	$ (0.55)	$ (0.56)
Net loss per share - diluted	$ (0.55)	$ (0.56)
Weighted average shares outstanding - basic	52,913	37,486
Weighted average shares outstanding - diluted	52,913	37,486
Net Income (Loss)	$ (29,284)	$ (21,164)
Other comprehensive loss:
Unrealized (loss) gain on available-for-sale securities, net of tax of $0 for periods presented	(28)	57
Comprehensive loss	(29,312)	(21,107)
Product [Member]
Revenues:
Total revenues	658	7,394
License and Collaboration Agreements [Member]
Revenues:
Total revenues	10,563	34
Royalty Income [Member]
Revenues:
Total revenues	$ 463	$ 255

EYPT Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 271,013	$ 281,263
Marketable securities	28,335	49,787
Accounts and other receivables, net	3,015	805
Prepaid expenses and other current assets	11,089	9,039
Inventory	4,257	3,906
Total current assets	317,709	344,800
Property and equipment, net	6,677	5,251
Operating lease right-of-use assets	4,711	4,983
Restricted cash	150	150
Total assets	329,247	355,184
Current liabilities:
Accounts payable	7,082	6,504
Accrued expenses	15,940	17,521
Deferred revenue	38,377	38,592
Other current liabilities	1,181	646
Total current liabilities	62,580	63,263
Deferred revenue - noncurrent	12,109	20,692
Operating lease liabilities - noncurrent	4,624	4,906
Total liabilities	79,313	88,861
Contingencies (Note 12)
Stockholders' equity:
Preferred stock, $.001 par value, 5,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $.001 par value, 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; 49,885,701 and 49,043,074 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	50	49
Additional paid-in capital	1,020,478	1,007,556
Accumulated deficit	(771,430)	(742,146)
Accumulated other comprehensive income	836	864
Total stockholders' equity	249,934	266,323
Total liabilities and stockholders' equity	$ 329,247	$ 355,184

About EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The company's pipeline leverages its proprietary erodible Durasert E technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment, which is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Jay S. Duker M.D.
WEBSITE	https://eyepointpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	144

EyePoint Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for EyePoint Pharmaceuticals Inc? What does EYPT stand for in stocks?

EYPT is the stock ticker symbol of EyePoint Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of EyePoint Pharmaceuticals Inc (EYPT)?

As of Fri May 17 2024, market cap of EyePoint Pharmaceuticals Inc is 616.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EYPT stock?

You can check EYPT's fair value in chart for subscribers.

What is the fair value of EYPT stock?

You can check EYPT's fair value in chart for subscribers. The fair value of EyePoint Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of EyePoint Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EYPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is EyePoint Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether EYPT is over valued or under valued. Whether EyePoint Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact EyePoint Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EYPT.

What is EyePoint Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, EYPT's PE ratio (Price to Earnings) is -7.81 and Price to Sales (PS) ratio is 12.32. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EYPT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on EyePoint Pharmaceuticals Inc's stock?

In the past 10 years, EyePoint Pharmaceuticals Inc has provided -0.108 (multiply by 100 for percentage) rate of return.